Based on the Biotest Aktiengesellschaft stock forecast from 0 analysts, the average analyst target price for Biotest Aktiengesellschaft is not available over the next 12 months. Biotest Aktiengesellschaft’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Biotest Aktiengesellschaft is Neutral, which is based on 8 positive signals and 7 negative signals. At the last closing, Biotest Aktiengesellschaft’s stock price was EUR 29.80. Biotest Aktiengesellschaft’s stock price has changed by -0.67% over the past week, +0.68% over the past month and +7.97% over the last year.
No recent analyst target price found for Biotest Aktiengesellschaft
No recent average analyst rating found for Biotest Aktiengesellschaft
Company Overview Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols Biotest Holdings GmbH. Read Less
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the ther...Read More
Frequently Asked Questions About Biotest Aktiengesellschaft (BIO3:F) Stock
Stock Target Advisor's fundamental analysis for Biotest Aktiengesellschaft's stock is Neutral.
BIO3:F stock's dividend yield is 0.13%.
Our analysis grades BIO3:F stock's dividend yield at F. This means that BIO3:F stock's dividend yield is above 5% of the stocks in the Biotechnology sector in the F exchange.
Based on this BIO3:F may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on BIO3:F's stock to indicate what its average analyst target is.
BIO3:F stock's Price/Earning ratio is 45.15.
Our analysis grades BIO3:F stock's Price / Earning ratio at F. This means that BIO3:F stock's Price/Earning ratio is above 68% of the stocks in the Biotechnology sector in the F exchange.
Based on this BIO3:F may be a overvalued for its sector.
The last closing price of BIO3:F's stock was EUR 29.80.
The most recent market capitalization for BIO3:F is EUR 1.44B.
Unfortunately we do not have enough analyst data on BIO3:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Biotest Aktiengesellschaft's stock.
As per our most recent records Biotest Aktiengesellschaft has 2,495 Employees.
Biotest Aktiengesellschaft's registered address is Landsteinerstrasse 5, Dreieich, Germany, 63303.
You can get more information about it from Biotest Aktiengesellschaft's website at https://www.biotest.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Biotest Aktiengesellschaft (BIO3:F) Stock
Stock Target Advisor's fundamental analysis for Biotest Aktiengesellschaft's stock is Neutral.
BIO3:F stock's dividend yield is 0.13%.
Our analysis grades BIO3:F stock's dividend yield at F. This means that BIO3:F stock's dividend yield is above 5% of the stocks in the Biotechnology sector in the F exchange.
Based on this BIO3:F may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on BIO3:F's stock to indicate what its average analyst target is.
BIO3:F stock's Price/Earning ratio is 45.15.
Our analysis grades BIO3:F stock's Price / Earning ratio at F. This means that BIO3:F stock's Price/Earning ratio is above 68% of the stocks in the Biotechnology sector in the F exchange.
Based on this BIO3:F may be a overvalued for its sector.
The last closing price of BIO3:F's stock was EUR 29.80.
The most recent market capitalization for BIO3:F is EUR 1.44B.
Unfortunately we do not have enough analyst data on BIO3:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Biotest Aktiengesellschaft's stock.
As per our most recent records Biotest Aktiengesellschaft has 2,495 Employees.
Biotest Aktiengesellschaft's registered address is Landsteinerstrasse 5, Dreieich, Germany, 63303.
You can get more information about it from Biotest Aktiengesellschaft's website at https://www.biotest.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIO3:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
